Characterization of RhoA-mediated Chemoresistance in Gastric Cancer Cells.
- Author:
Won Ki KANG
1
;
Inkyoung LEE
;
Chaehwa PARK
Author Information
1. Cancer Center, Samsung Medical Center, and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. cpark@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
Rho;
Resistance;
Microarray analysis
- MeSH:
Actin Cytoskeleton;
Blotting, Western;
Cell Death;
Cell Line;
Cisplatin;
Etoposide;
Fluorouracil;
Glucose;
Lovastatin;
Metabolism;
Microarray Analysis;
Oligonucleotide Array Sequence Analysis;
Paclitaxel;
Stomach Neoplasms*;
Transcriptome;
Transducers;
Vincristine
- From:Cancer Research and Treatment
2005;37(4):251-256
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: RhoA is a critical transducer of extracellular signals, which leads to organization of actin cytoskeleton, motility, adhesion and gene regulation. The present study aimed to explore whether RhoA influences the susceptibility of gastric cancer cells to chemotherapeutic drugs. MATERIALS AND METHODS: SNU638 cells were transfected with a mock vector (pcDNA3.1), RhoA (pcDNA/RhoA), or constitutively active RhoA (pcDNA/caRhoA). MTT assay and Western blot analysis were performed to study the growth response to several chemotherapeutic drugs in the gastric cancer cell line, SNU638, with different RhoA levels. RESULTS: RhoA significantly enhanced the resistance to lovastatin, 5-FU, taxol and vincristine, but did not affect the sensitivity to cisplatin or etoposide in SNU638. In the Western blot analysis, RhoA decreased the PARP cleavage, which was accompanied by a concurrent reduction in cell death. The gene expression profile after a cDNA microarray analysis demonstrated that RhoA was associated with the differential expression of 19 genes, including those involved in anti-oxidant defense, glucose metabolism, anti-apoptosis and protein turnover. CONCLUSION: Gastric cancer cells with a high expression of RhoA could be resistant to chemotherapeutic drugs, such as taxol or vincristine, implying that treatment strategies aimed at inactivation of RhoA might be promising for improving the efficacy of these chemotherapeutic drugs.
